Clik here to view.
Julian Costas joins Clarivate Analytics as Global Head, Business Development,...
Julian Costas joins Clarivate Analytics as the Global Head, Business Development, Licensing and Portfolio Strategy. Julian will be responsible for growing and scaling the company’s existing consulting...
View ArticleClik here to view.
New Clarivate Analytics report shows the cost to bring a drug to market has...
Pharmaceutical R&D industry report provides insights into what’s behind decade-high drug approval rates and reveals implications of costs and sustainability London, UK, & Philadelphia, US –...
View ArticleClik here to view.
Clarivate Analytics introduces next-generation pre-clinical drug research...
Updated solution enables enhanced analytics and greater utility of biology, chemistry and pharmacology data—within a single application London, UK, & Philadelphia, US – October 1, 2019 – Clarivate...
View ArticleClik here to view.
Report: Biopharma licensing eclipsed $33 billion in Q2 2019
Earlier this year, we released an in-depth analysis of 2018 biopharma deals activity. Today’s blog examines more recent biopharma partnering activities, focusing on licensing deals in the second...
View ArticleClik here to view.
Cortellis report: M&A value decreases by 7% to $105.3bn in Q2 2019
In early 2019, we released an in-depth analysis of 2018 deals activity. Here, we examine more recent activities and discuss mergers and acquisitions in the second quarter of 2019. More deals, but...
View ArticleClik here to view.
Uncovering the potential cause of rare diseases
Cortellis analysts apply a systems biology approach to identifying digeneic inheritance. Although rare diseases affect a small percentage of the population, the U.S. research organization Global Genes...
View ArticleClik here to view.
Tenofovir alafenamide fumarate raises targeting questions
In the race to bring generic drugs to market, Paragraph IV patent challenges are now an unavoidable fact of life. The question is no longer if there will be a patent challenge, but when and by whom. In...
View ArticleDiverse approaches in immuno-oncology
A fascinating range of insights into the ways in which the immune system can be harnessed to fight cancer was provided by Global Engage’s Immuno-Oncology Research & Technology Series meeting this...
View ArticleExpected blockbusters: A year in progress
Earlier this year, we released the Cortellis Drugs to Watch 2019 report, which highlighted seven drugs expected to launch in 2019 and become blockbusters in 2023. We have subsequently reported on three...
View ArticleClik here to view.
Q&A: Five simple strategies to ensure regulatory compliance when globalizing...
Industry expert Lawrence Liberti shares his tips for tackling the complexity and diversity of regulatory requirements in divergent markets While expansion into new markets potentially introduces...
View ArticleIndia: The emerging hub for biologics and biosimilars
The global pharmaceutical industry is facing a shift from chemical-based drugs to biologics and biosimilars. While small molecule therapeutics had previously dominated research and captured major...
View ArticleClik here to view.
Q3 2019 M&A highlights
We’ve recently wrapped up analysis of Q3 2019 M&A activity around the world. Here are a few highlights: Q3 2019 new M&A volume and total deal value increased by 4% and 10%, respectively Total...
View ArticlePharmaceutical innovation in the APAC region
A first-of-its-kind study paints a vivid picture of the APAC region’s future with a data-driven analysis that ranked companies on their degree of innovation, using a methodology expressly developed for...
View ArticleClik here to view.
Clarivate Analytics expands global life science alliances program with three...
Enabling extended use of its life science intelligence solutions to help companies accelerate innovation London, UK, & Philadelphia, US, December 5, 2019 – Clarivate Analytics plc (NYSE:CCC;...
View ArticlePharma disruptors, challenges and opportunities
The recent Financial Times Global Pharmaceutical and Biotechnology Conference provided two days of fascinating insights into the pharma industry, with discussions around the key challenges, disruptors...
View ArticleClik here to view.
Biopharma licensing activity in Q3 2019 51.8% higher than in Q3 2018
Total disclosed biopharma licensing exhibited strong growth in worldwide spend during the third quarter of 2019, driving a 51.8% increase to $37.2 billion from $24.5 billion in the same time period in...
View ArticleThe microbiome mystery: Gaining insights through data mining and analysis
The recent buzz around the microbiome and its effects on human health has both generated and resulted from an exponential growth in research and related publications. In fact, there’s been a 5000%...
View ArticleBenefits of HTA implementation in the Middle East and North Africa
Health Technology Assessment (HTA) has become one of the most anticipated regulatory advancements across the Middle East and North Africa (MENA) due to its potential to modernize healthcare systems...
View ArticleClik here to view.
Clarivate Analytics to Acquire Decision Resources Group, Creating a Leading...
Deal expands Life Sciences services and solutions portfolio to enable customers worldwide to accelerate life-changing innovations and improve patient outcomes and access Accretive to earnings in 2020...
View ArticleGet the insights you need on the Coronaviruses from Clarivate Analytics
Access the world’s leading research and late-breaking news on this rapidly evolving health emergency. A global health emergency can occur without warning, as we are currently experiencing with the...
View Article